Vaxcyte vs Suzhou Zelgen Biopharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Vaxcyte Inc (PCVX)

Q3 20266 Sep – 6 Oct 2026

▲3▼1

VAX-31 Phase 3 Win Lifts Vaxcyte; $1B Raise Dilutes

VAX-31 hits Phase 3 goals, stock jumps Vaxcyte's lead vaccine VAX-31 met all main goals in a late-stage trial, matching Pfizer's and Merck's shots and beating them on some strains. The stock soared 57% to a 52-week high. This success is the biggest driver, making approval and launch much more likely.
This is the key event that directly caused the stock's massive jump and changes the company's outlook.
$1B capital raise dilutes shareholders Vaxcyte launched $1 billion in stock and convertible notes to fund VAX-31 development and launch. The stock fell 3.7% as investors worried about dilution. While the cash strengthens the balance sheet, it spreads future profits over more shares, pressuring the price short-term.
This is a new event that directly impacts the stock price and capital structure.
Data timing moved up to late October Vaxcyte narrowed its VAX-31 Phase 3 OPUS-1 readout to late October, earlier than the prior fourth-quarter guidance. This accelerated catalyst timeline raised expectations and is a positive driver, as it brings clarity and potential near-term value inflection.
This is a new update that changes the timing of a major catalyst, influencing investor sentiment.
Key executive hires bolster launch prep Vaxcyte added Pfizer's former vaccines chief medical officer and Teva's former legal head. These hires bring deep experience in vaccine development and commercialization, strengthening the company's ability to execute on VAX-31's regulatory and launch plans, which supports the stock.
This is a new development that enhances the company's leadership and execution capabilities.

September 20266 Sep – 6 Oct 2026

▲3▼1

VAX-31 Phase 3 Win Lifts Vaxcyte; $1B Raise Dilutes

VAX-31 hits Phase 3 goals, stock jumps Vaxcyte's lead vaccine VAX-31 met all main goals in a late-stage trial, matching Pfizer's and Merck's shots and beating them on some strains. The stock soared 57% to a 52-week high. This success is the biggest driver, making approval and launch much more likely.
This is the key event that directly caused the stock's massive jump and changes the company's outlook.
$1B capital raise dilutes shareholders Vaxcyte launched $1 billion in stock and convertible notes to fund VAX-31 development and launch. The stock fell 3.7% as investors worried about dilution. While the cash strengthens the balance sheet, it spreads future profits over more shares, pressuring the price short-term.
This is a new event that directly impacts the stock price and capital structure.
Data timing moved up to late October Vaxcyte narrowed its VAX-31 Phase 3 OPUS-1 readout to late October, earlier than the prior fourth-quarter guidance. This accelerated catalyst timeline raised expectations and is a positive driver, as it brings clarity and potential near-term value inflection.
This is a new update that changes the timing of a major catalyst, influencing investor sentiment.
Key executive hires bolster launch prep Vaxcyte added Pfizer's former vaccines chief medical officer and Teva's former legal head. These hires bring deep experience in vaccine development and commercialization, strengthening the company's ability to execute on VAX-31's regulatory and launch plans, which supports the stock.
This is a new development that enhances the company's leadership and execution capabilities.

Latest6 Sep – 6 Oct 2026

▲3▼1

VAX-31 Phase 3 Win Lifts Vaxcyte; $1B Raise Dilutes

VAX-31 hits Phase 3 goals, stock jumps Vaxcyte's lead vaccine VAX-31 met all main goals in a late-stage trial, matching Pfizer's and Merck's shots and beating them on some strains. The stock soared 57% to a 52-week high. This success is the biggest driver, making approval and launch much more likely.
This is the key event that directly caused the stock's massive jump and changes the company's outlook.
$1B capital raise dilutes shareholders Vaxcyte launched $1 billion in stock and convertible notes to fund VAX-31 development and launch. The stock fell 3.7% as investors worried about dilution. While the cash strengthens the balance sheet, it spreads future profits over more shares, pressuring the price short-term.
This is a new event that directly impacts the stock price and capital structure.
Data timing moved up to late October Vaxcyte narrowed its VAX-31 Phase 3 OPUS-1 readout to late October, earlier than the prior fourth-quarter guidance. This accelerated catalyst timeline raised expectations and is a positive driver, as it brings clarity and potential near-term value inflection.
This is a new update that changes the timing of a major catalyst, influencing investor sentiment.
Key executive hires bolster launch prep Vaxcyte added Pfizer's former vaccines chief medical officer and Teva's former legal head. These hires bring deep experience in vaccine development and commercialization, strengthening the company's ability to execute on VAX-31's regulatory and launch plans, which supports the stock.
This is a new development that enhances the company's leadership and execution capabilities.

Suzhou Zelgen Biopharmaceuticals Co Ltd (688266.CG)

Q3 202621 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.

August 202621 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.

Latest21 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.